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Abstract
Introduction: Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness. Prior trials have
demonstrated the efficacy of pregabalin for the relief of fibromyalgia symptoms, and it is approved for the
treatment of fibromyalgia in the United States. However, prior to this study, there has not been a large-scale
efficacy trial in patients with fibromyalgia in Japan.
Methods: This randomized, double-blind, multicenter, placebo-controlled trial was conducted at 44 centers in
Japan to assess the efficacy and safety of pregabalin for the symptomatic relief of pain in fibromyalgia patients.
Patients aged ≥18 years who had met the criteria for fibromyalgia were randomized to receive either
pregabalin, starting at 150 mg/day and increasing to a maintenance dose of 300 or 450 mg/day, or placebo,
for 15 weeks. The primary efficacy endpoint was mean pain score at final assessment. Secondary endpoints
included Patient Global Impression of Change (PGIC) together with measures of sleep, physical functioning and
quality of life.
Results: A total of 498 patients (89% female) were randomized to receive either pregabalin (n = 250) or placebo
(n = 248). Pregabalin significantly reduced mean pain score at final assessment (difference in mean change from
baseline, compared with placebo -0.44; P = 0.0046) and at every week during the study (P <0.025). Key secondary
endpoints were also significantly improved with pregabalin treatment compared with placebo, including PGIC
(percentage reporting symptoms “very much improved” or “much improved”, 38.6% vs 26.7% with placebo; P = 0.0078);
pain visual analog scale (difference in mean change from baseline, compared with placebo -6.19; P = 0.0013);
Fibromyalgia Impact Questionnaire total score (-3.33; P = 0.0144); and quality of sleep score (-0.73; P <0.0001). Treatment
was generally well tolerated, with somnolence and dizziness the most frequently reported adverse events.
Conclusions: This trial demonstrated that pregabalin, at doses of up to 450 mg/day, was effective for the
symptomatic relief of pain in Japanese patients with fibromyalgia. Pregabalin also improved measures of sleep and
functioning and was well tolerated. These data indicate that pregabalin is an effective treatment option for the
relief of pain and sleep problems in Japanese patients with fibromyalgia.
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Introduction
Fibromyalgia (FM) is a common chronic pain disorder
characterized by widespread pain and tenderness [1-5].
Associated symptoms include fatigue, sleep disturbance,
headache, mood disorders and memory or concentration
problems [1,6,7]. Of the symptoms of FM, both patients
and clinicians have ranked pain as the most important
[6]. An estimate of the prevalence of FM in Japan by a
Ministry of Health, Labor and Welfare study group was
1.7%, with a higher incidence in women (male-to-female
ratio 1:4.8) and a mean age of 51.5 ± 16.9 years [8,9].
However, FM remains an underdiagnosed disease and it
can be challenging for patients to obtain appropriate
treatment. At the time of this study, there was no
approved medication for FM in Japan. Pregabalin was
approved in Japan for the treatment of pain associated
with FM in June 2012.
Previous trials conducted in the United States (US)
[10-13] and internationally [14] have demonstrated the
safety and efficacy of pregabalin, an a2δ ligand with
analgesic and anticonvulsant activity [15], in the treatment
of FM. In these trials, pregabalin (at 300 to 600 mg/day)
demonstrated significant improvements in pain, sleep,
function and patient impressions of change compared
with placebo [10-14]. However, prior to the current study,
there has not been a clinical trial conducted in FM
patients in Japan.
The objective of this trial was to assess the efficacy and
safety of pregabalin (300 or 450 mg/day) compared with
placebo in patients with FM in Japan. The primary objec-
tive was to assess the effect of pregabalin on the sympto-
matic relief of pain. Key secondary objectives included
evaluation of the safety and tolerability of pregabalin,
together with its effect on sleep, physical functioning,
patient impressions of change and health-related quality
of life.
Materials and methods
Study design
This was a randomized, double-blind, multicenter, pla-
cebo-controlled trial to compare the efficacy and safety
of pregabalin vs placebo in patients with FM. The study
was conducted at 44 study centers in Japan between
March 2009 and May 2011. Patients were randomized to
receive pregabalin, starting at 150 mg/day and increasing
to a maintenance dose of 300 or 450 mg/day, or placebo.
The study included a 1-week, single-blind, placebo run-
in period; a 3-week dose-escalation/optimization phase; a
12-week, fixed-dose treatment period; and a 1-week taper
phase (Figure 1).
Patients were registered to the randomization control
system (IMPALA), which provided subject randomiza-
tion numbers. Pregabalin and identical placebo capsules
were prescribed by the investigator using blinded drug
numbers issued by IMPALA.
This study was conducted in accordance with the
International Conference on Harmonization guidelines
on Good Clinical Practice. The study protocol and
informed consent documents were approved by the rele-
vant Institutional Review Boards and Independent Ethics
Committees. Written informed consent was obtained
from all patients prior to their inclusion in the study.
This study is registered at clinicaltrials.gov under the
identifier NCT00830167.
Patient population
Methodology and screening criteria were similar to those
used in previously reported studies of pregabalin [10,14].
Patients were aged ≥18 years and had met the 1990 ACR
(American College of Rheumatology) criteria for FM [1].
Patients also had a score of ≥40 mm on the 100 mm pain
visual analog scale (VAS) at Visit 2, and had assessed and
documented their pain score on at least four of the past
seven days prior to Visit 2 while recording an average
pain score of ≥4 on the 11-point numeric rating scale.
Patients were excluded if they had a decrease of ≥30% on
their pain VAS during the placebo run-in period (at
Visit 2 compared with Visit 1), in order to remove poten-
tial placebo-responders. Patients were also excluded if
they were being treated for depression, were at risk of
suicide or self-harm in the opinion of the study investiga-
tor, had an active malignancy or a history of malignancy,
had a creatinine clearance rate ≤60 ml/min, or experi-
enced pain which might potentially affect assessment or
self-evaluation of FM.
Study medication
Dosing was twice each day (morning and evening) based
on the US prescribing information for pregabalin in FM
[16]. The individual investigators decided whether to
advise patients to take the study drug before or after
meals, and patients were directed to take medication in
the same manner throughout the study. Treatment was
started at 150 mg/day, escalated to 300 mg/day one
week later, and to 450 mg/day after another week. The
dose was adjusted (increased or decreased) until Visit 5
of the study, after which the maintenance dose was
either 300 mg/day or 450 mg/day.
Desensitization methods that would affect the assess-
ment of pain associated with FM, such as non-drug thera-
pies (for example, physical therapy, massage, chiropractry,
psychotherapy, counseling) were not permitted within
30 days of the start of the screening phase through to the
end of the study. Patients were permitted to use acetami-
nophen (≤1.5 g/day) or nonsteroidal anti-inflammatory
drugs (NSAIDs) for additional pain relief, although for
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NSAIDs, the patient must have already been on a stable
regimen for longer than 30 days and the dosage was not to
be changed. The majority of patients had some concomi-
tant drug use during the trial: 87.6% of patients in the
pregabalin group and 88.7% of patients in the placebo
group. The most common (in ≥10% of patients) were
paracetamol (27.2% pregabalin, 31.5% placebo), mydrin
P (28.4% pregabalin, 29.8% placebo), rebamipide (12.8%
pregabalin, 14.1% placebo) and loxoprofen sodium (10%
pregabalin, 12.1% placebo).
Efficacy assessments
The primary efficacy endpoint was the mean pain score at
final assessment as recorded by patients in their daily pain
diaries over the past seven days, measured using an
11-point (0 (no pain) to 10 (worst possible pain)) numeric
rating of the amount of pain over the past 24 hours
[17,18]. The mean pain score was assessed at each week
during the treatment phase until final assessment.
There were several secondary endpoints: pain VAS,
with scores ranging from 0 (no pain) to 100 mm (worst
possible pain); Patient Global Impression of Change
(PGIC), a patient-rated instrument measuring the change
in overall status on a scale of 1 (very much improved) to
7 (very much worse) [17]; FM Impact Questionnaire
(FIQ; Japanese version), a self-administered questionnaire
with 10 subscales measuring FM symptom and function
domains, with the total score ranging from 0 (no impact)
to 100 (maximum impact) [19,20]; SF-36 health survey
measuring health-related quality of life [21]; Hospital
Anxiety and Depression Scales (HADS) measuring the
presence and severity of symptoms of anxiety and depres-
sion [22]; quality of sleep score assessed by an 11-point
numeric rating scale ranging from 0 (best possible sleep)
to 10 (worst possible sleep) and expressed as a mean
value over the past seven days [23]; Medical Outcomes
Study (MOS)-Sleep Scale, a 12-item questionnaire yield-
ing 7 subscales, each scored from 0 to 100, with higher
scores indicating more of the attribute named in the sub-
scale except for ‘sleep quantity’, which was scored from
0 to 24 (indicating the number of hours of sleep) and
‘optimal sleep’, scored as the number of patients report-
ing optimal sleep [24].
Safety and tolerability
Safety and tolerability were assessed by the study investi-
gator by monitoring adverse events (AEs); the severity of
each AE and its relationship to the study drug were
recorded at each visit. Assessments included: body
weight, blood pressure, pulse rate, physical examinations,
edema assessment, neurological examinations and
ophthalmologic examinations, 12-lead electrocardiogram,
clinical laboratory testing (hematology, serum chemistry,
urinalysis), and Columbia-Suicide Severity Rating Scale
(C-SSRS), in addition to progression/worsening of under-
lying disease.
Statistical analysis
Based on results from prior studies of pregabalin in FM
[10,12-14], a sample size of 498 patients was estimated to
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Figure 1 Study design.
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be sufficient to detect a clinically significant difference (at
the level of 0.025 for a one-sided test) in the primary
endpoint.
The primary analysis was a comparison between the
pregabalin and placebo groups at final assessment and
was based on an analysis of covariance model, including
dose groups and baseline mean pain score as factors. The
mean pain score was also calculated each week in the
treatment phase and analyzed as the time-course mea-
surement data. A mixed-effect model taking baseline
value as covariate was used for the analysis, which
included patients as the random effect and dose groups,
points at time of evaluation, and interaction between a
dose group and its point at time of evaluation as the
fixed effects. A one-sided test with a significance level of
0.025 was used for analyses other than mean pain score
responders (patients with a ≥30% or ≥50% reduction in
their mean pain score at final assessment) and PGIC,
which used a two-sided test with significance level of
0.05. All final assessment measures were determined
using last observation carried forward (LOCF).
Efficacy analyses were performed for all patients who
had received ≥1 dose of treatment and had ≥1 entry in
their daily pain diary while on study medication. Safety
analyses were performed for all patients who had
received ≥1 dose of treatment.
Results
Patient population
A total of 501 patients were randomized (251 to pregaba-
lin and 250 to placebo), of whom 498 received ≥1 dose of
study drug (250 pregabalin and 248 placebo); 415 com-
pleted the trial (Figure 2). Of the 250 patients receiving ≥1
dose of pregabalin treatment, 59 received 300 mg/day
from the start of the fixed-dose period (Week 3), while
178 received 450 mg/day (13 patients discontinued prior
to Week 3 of the study). The overall study population was
predominantly female with 443 women (89%) and 55 men
(11%). The mean age was 47.9 years in the pregabalin
group and 46.7 years in the placebo group. Demographic
characteristics of patients assigned to each treatment arm
were comparable (Table 1). The mean (range) number of
months since FM onset was 62.0 (0.3, 508.8) in the pla-
cebo group and 69.6 (0.3, 505.1) in the pregabalin group.
Overall, 83 patients withdrew from the study (40 in the
placebo group and 43 in the pregabalin group), with 19
withdrawing from the pregabalin group due to an AE
related to the study drug.
Pain responses
Mean pain score at final assessment was reduced from
baseline with both pregabalin (a reduction of 1.48 to 5.01
final score) and placebo (a reduction of 1.03 to 5.45). The
difference in reduction in pain score with pregabalin treat-
ment compared with placebo was statistically significant
(-0.44; 95% CI (-0.78, -0.11); P = 0.0046). Baseline mean
(± standard deviation) pain scores were similar for the
pregabalin (6.5 ± 1.3) and placebo groups (6.4 ± 1.3). Preg-
abalin treatment also resulted in a statistically signifi-
cant improvement in the weekly least squares (LS)
mean pain score at every time point compared with pla-
cebo (Figure 3).
Figure 2 Patient disposition.
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Patients with a ≥50% reduction in their mean pain
score at final assessment (≥50% responders) accounted
for 22.8% (57 of 250) of the pregabalin group compared
with 12.1% (30 of 248) of the placebo group; this differ-
ence was statistically significant (P = 0.0017). This repre-
sents a number needed to treat (NNT) of 10. Patients
with a ≥30% reduction in their mean pain score at final
assessment (≥30% responders) accounted for 40.4% (101
of 250) of the pregabalin group compared with 30.6% (76
of 248) of the placebo group; this difference was also sta-
tistically significant (P = 0.0230).
Patients treated with pregabalin demonstrated a statis-
tically significant improvement in pain VAS score at
final assessment when compared with the placebo group
(LS mean score at final assessment, 47.42 (SE, 1.44); dif-
ference from placebo -6.19; 95% CI (-10.20, -2.18); P =
0.0013). In addition, there was a statistically significant
improvement at each time point at which pain VAS was
assessed from Week 1 to Week 15 (Figure 4). Baseline
mean (± standard deviation) pain VAS scores were simi-
lar for the pregabalin (68.3 ± 13.1) and placebo groups
(67.2 ± 13.1).
Patient Global Impression of Change
The proportion of patients who reported a notable
improvement in their PGIC (either “very much
improved” or “much improved” [17]) was higher in the
pregabalin group (38.6%; 96 of 249 patients) than in the
placebo group (26.7%; 66 of 247 patients). Overall,
patients treated with pregabalin demonstrated a statisti-
cally significantly greater improvement compared with
the placebo group (P = 0.0078) (Table 2).
Fibromyalgia Impact Questionnaire
There was a significantly greater improvement in FIQ
total score in the pregabalin group (LS mean change
from baseline, -10.59) compared with the placebo group
(-7.26) (difference from placebo, -3.33; 95% CI (-6.31,
-0.35); P = 0.0144) (Table 3). The subscales of feeling
good, pain, fatigue and morning tiredness were all sig-
nificantly improved with pregabalin treatment compared
Figure 3 Weekly LS mean change in pain score from baseline.
Weekly assessment analyses based on the results of the mixed-effect
model repeated measure (MMRM) analysis with weekly pain score
defined as the mean of the last seven daily diary pain ratings. Mean
value (± SE) shown for each week, where *P <0.025, **P <0.001 and
***P <0.0001 for each treatment time point compared with placebo.
Figure 4 LS mean pain VAS score. Weekly assessment analyses
based on the results of the MMRM analysis with weekly mean VAS
score. Scores range from 0 to 100 with higher scores indicating
increased pain. Mean value (± SE) shown for each time point, where
*P ≤0.025, **P ≤0.001 and ***P ≤0.0001 for each treatment time
point compared with placebo.
Table 1 Patient characteristics
Placebo
N = 248
Pregabalin
N = 250
Sex, n (%)
Male 31 (12.5) 24 (9.6)
Female 217 (87.5) 226 (90.4)
Hormonal status, n (%)
Premenopausal 133 (61.3) 140 (61.9)
Postmenopausal 84 (38.7) 86 (38.1)
Age (years)
<18, n (%) 0 0
18 to 44, n (%) 104 (41.9) 101 (40.4)
45 to 64, n (%) 123 (49.6) 125 (50.0)
≥65, n (%) 21 (8.5) 24 (9.6)
Mean ± SD 46.7 ± 12.6 47.9 ± 12.0
Range 19, 78 19, 80
Weight, kg
Mean ± SD 56.2 ± 9.0 55.5 ± 11.0
Range 38.9, 90.9 37.2, 104.8
Height, cm
Mean ± SD 158.5 ± 6.8 158.3 ± 6.4
Range 131.9, 179.6 143.8, 176.0
Duration since FM onset, months
Mean 62.0 69.6
Range 0.3, 508.8 0.3, 505.1
FM, fibromyalgia; SD, standard deviation
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with placebo, whereas the subscales of physical function-
ing, housework, anxiety and stiffness showed a numerical
improvement that was not statistically significant.
Health-related quality of life
The SF-36 survey revealed statistically significant
improvements in physical functioning (P = 0.0006) and
vitality (P = 0.0052) in the pregabalin group compared
with the placebo group (Table 3). There was a numerical,
but not statistically significant, trend towards improve-
ment in the pregabalin group compared with the placebo
group for mental health, bodily pain, general health per-
ception, physical role limitations and social functioning.
However, there was no significant difference between the
groups for the assessment of emotional role limitations.
Anxiety and depression
Mean baseline scores (± standard deviation) for the
anxiety and depression subscales of the HADS were
similar for the pregabalin (anxiety, 6.0 ± 4.1; depression,
6.1 ± 4.2) and placebo groups (anxiety, 5.8 ± 3.7;
depression, 5.9 ± 3.8). Although there was a trend
towards improvement in the anxiety subscale in the
pregabalin group (LS mean score at endpoint, 5.29)
compared with the placebo group (5.77), the difference
was not statistically significant (LS mean change, differ-
ence from placebo -0.48; 95% CI (-0.97, 0.01); P =
0.0262). Similarly, there was a trend towards improve-
ment in the depression subscale in the pregabalin group
(LS mean score at endpoint, 5.71) compared with the
placebo group (5.99), which was not significant (LS
mean change, difference from placebo -0.28; (-0.83,
0.27); P = 0.1561).
Table 2 Patient Global Impression of Change at final
assessment
Placebo Pregabalin
Number assesseda 247 249
Very much improved 16 (6.5)b 31 (12.4)
Much improved 50 (20.2) 65 (26.1)
Minimally improved 88 (35.6) 79 (31.7)
No change 60 (24.3) 43 (17.3)
Minimally worse 14 (5.7) 14 (5.6)
Much worse 13 (5.3) 13 (5.2)
Very much worse 6 (2.4) 4 (1.6)
P-valuec 0.0078
aNumber of patients with available data for this analysis. bNumber (%) of
patients. cBased on chi-square test with a modified rigid transformation.
Table 3 Fibromyalgia Impact Questionnaire and SF-36 scores at baseline and final assessment
Assessment Baseline mean
score ± SD
Final assessment LS mean
score ± SE
Placebo-adjusted LS mean change from baseline
with pregabalina
Placebo Pregabalin Placebo Pregabalin Change 95% CI P-value
FIQ scoreb
Morning tiredness 6.6 ± 2.1 6.8 ± 2.2 5.73 ± 0.15 5.13 ± 0.15 -0.59 -1.01, -0.18 0.0023*
Feeling good 6.7 ± 2.6 6.8 ± 2.6 5.94 ± 0.17 5.30 ± 0.17 -0.63 -1.12, -0.15 0.0052*
Fatigue 6.8 ± 1.9 7.0 ± 1.9 5.94 ± 0.14 5.45 ± 0.14 -0.49 -0.89, -0.10 0.0075*
Pain 6.4 ± 1.6 6.5 ± 1.6 5.36 ± 0.15 4.95 ± 0.15 -0.41 -0.81, 0.00 0.0238*
Physical functioning 3.2 ± 2.3 3.3 ± 2.4 3.03 ± 0.11 2.74 ± 0.11 -0.28 -0.59, 0.03 0.0376
Housework 5.5 ± 2.4 5.7 ± 2.5 4.61 ± 0.15 4.30 ± 0.15 -0.31 -0.74, 0.11 0.0729
Anxiety 4.5 ± 2.6 4.6 ± 2.6 3.92 ± 0.16 3.64 ± 0.16 -0.28 -0.72, 0.15 0.1011
Stiffness 5.9 ± 2.5 6.0 ± 2.5 5.05 ± 0.15 4.90 ± 0.15 -0.14 -0.57, 0.29 0.2568
Depression 3.9 ± 2.7 3.9 ± 2.6 3.38 ± 0.14 3.34 ± 0.14 -0.04 -0.44, 0.35 0.4165
Missing work 2.2 ± 3.0 2.2 ± 3.1 1.89 ± 0.15 1.87 ± 0.15 -0.01 -0.42, 0.40 0.4768
Total FIQ score 51.6 ± 15.0 52.7 ± 15.3 44.89 ± 1.08 41.56 ± 1.07 -3.33 -6.31, -0.35 0.0144*
SF-36 health surveyc
Physical functioning 64.0 ± 20.9 63.4 ± 20.8 68.44 ± 0.93 72.73 ± 0.93 4.29 1.70, 6.88 0.0006*
Vitality 37.6 ± 19.4 36.2 ± 20.5 42.01 ± 1.22 46.43 ± 1.21 4.42 1.04, 7.80 0.0052*
Mental health 62.1 ± 18.0 60.1 ± 20.3 64.47 ± 0.98 67.11 ± 0.98 2.64 -0.08, 5.37 0.0287*
Bodily pain 34.6 ± 14.1 33.0 ± 14.0 43.27 ± 1.06 45.42 ± 1.06 2.15 -0.81, 5.10 0.0770
General health perception 42.6 ± 15.7 41.4 ± 16.0 44.82 ± 0.85 46.65 ± 0.85 1.83 -0.54, 4.19 0.0648
Physical role limitations 52.3 ± 26.1 52.7 ± 27.9 60.90 ± 1.30 62.58 ± 1.30 1.68 -1.93, 5.29 0.1805
Social functioning 61.4 ± 26.0 61.9 ± 28.2 68.51 ± 1.38 70.10 ± 1.37 1.59 -2.23, 5.41 0.2068
Emotional role limitations 71.7 ± 26.6 67.2 ± 27.2 72.99 ± 1.36 72.76 ± 1.35 -0.23 -4.00, 3.54 0.5480
aDifference in mean change from baseline compared with placebo, using the baseline score as covariate. bFIQ scores for each assessment range from 0 to 10,
with higher scores indicating greater impairment (total score range is from 0 to 100). cSF-36 health survey scores range from 0 to 100, with higher scores
indicating better patient status. *Indicates statistical significance at the P <0.025 level. CI, confidence interval; FIQ, Fibromylagia Impact Questionnaire; LS, least
squares; SD, standard deviation; SE, standard error.
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Quality of sleep
Baseline mean (± standard deviation) sleep quality scores
were similar for the pregabalin (5.8 ± 1.7) and placebo
(5.6 ± 1.7) groups. The LS mean change in quality of sleep
score was significantly better in the pregabalin group (as
shown by a reduction of 1.52 to 4.17) compared with the
placebo group (reduction of 0.79 to 4.91) at final assess-
ment (pregabalin difference from placebo, -0.73; 95% CI
(1.06, -0.40); P <0.0001), and at every time point from
Week 1 through Week 15 (P ≤0.0001) (Figure 5).
Patients treated with pregabalin showed significant
improvement in the following MOS-Sleep Scale question-
naire items: sleep disturbance (P <0.0001), sleep adequacy
(P <0.0001), quantity of sleep (P = 0.0007), awakening
short of breath or with headache (P = 0.0049) and the
composite overall sleep problems index (P = 0.0137), com-
pared with placebo (Table 4). There was a trend towards
an increase in the proportion of patients reporting optimal
sleep in the pregabalin group (28.5%; 71 of 249 patients)
compared with the placebo group (21.5%; 53 of 247
patients), but this was not statistically significant (P =
0.0687). Scores on the snoring and somnolence subscales
were increased (worsened) with pregabalin compared with
placebo (Table 4).
Safety and tolerability
The incidence of all-causality AEs was higher in the preg-
abalin group (occurring in 225 of 250 patients, 90.0%)
than in the placebo group (175 of 248 patients, 70.6%)
(Table 5). Similarly, the incidence of treatment-related
AEs was higher in the pregabalin group (206 of 250
patients, 82.4%) than in the placebo group (128 of 248
patients, 51.6%). The most common AEs in this study
were somnolence, dizziness, nasopharyngitis, increased
weight and constipation with pregabalin treatment, and
somnolence and nasopharyngitis with placebo (Table 5).
A greater proportion of patients in the pregabalin group
than in the placebo group withdrew from the study
because of all-cause AEs (9.6% vs 3.6%, respectively).
This represents a number needed to harm (NNH) of 16.
The all-cause AEs resulting in withdrawal from the study
in more than one patient in the pregabalin group were
somnolence (eight patients), dizziness (five patients) and
insomnia (two patients).
A laboratory test result of increased creatine kinase
was more frequent in the pregabalin group (7 of 250
patients, 2.8%) than in the placebo group (1 of 248
patients, 0.4%), although all cases were of mild severity.
Increased weight was reported more frequently in the
pregabalin group (39 of 250 patients, 15.6% (38 mild,
1 moderate)) than in the placebo group (9 of 248
patients, 3.6% (8 mild, 1 moderate)). There were no
clinically significant changes in blood pressure or pulse
rate in the pregabalin group.
There were four serious AEs in four patients (0.8%)
who had received ≥1 dose of treatment; one patient was
from the placebo group (abnormal liver function test
result) and three were from the pregabalin group (breast
cancer, viral gastroenteritis and musculoskeletal stiff-
ness). Severe AEs were observed in two patients from
the pregabalin group (breast cancer and loss of con-
sciousness, each in one patient) and all other AEs were
mild or moderate. As assessed by the study investiga-
tors, there was no causal relationship to the study drug
for any serious or severe AEs.
Suicidal ideation (mild), as rated by C-SSRS, was noted
in two patients in the pregabalin group. The investigator
(a physician specializing in psychosomatic medicine) had
noted suicidal ideation in each of these patients prior to
the start of the study. In each case, incidence was attribu-
table to family environment and was judged to have no
causal relationship to the study drug. The suicidal ideation
in these cases was not judged by the study investigator to
be a real desire, and treatment with the study drug was
continued.
Discussion
This randomized controlled trial demonstrated the effi-
cacy and safety of pregabalin (300 or 450 mg/day) for the
treatment of Japanese patients with FM. Improvements
in mean pain score and pain VAS score were observed
within one week and continued for the duration of the
study. Treatment also significantly improved physical
functioning, health-related quality of life and subjective
measures of sleep.
Previous randomized, double-blind, placebo-controlled
trials conducted in the US demonstrated the efficacy of
pregabalin (300, 450 and 600 mg/day) on pain, PGIC and
Figure 5 Weekly LS mean sleep quality score . Weekly
assessment analyses based on the results of the MMRM analysis
with weekly mean sleep quality score defined as the mean of the
last seven daily diary sleep quality ratings. Scores range from 0 to
10 with higher scores indicating decreased sleep quality. Mean
value (± SE) shown for each week, where ***P ≤0.0001 for each
treatment time point compared with placebo.
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sleep over 8 [12], 13 [13] and 14 [10] weeks in FM
patients. Collectively, the results from these trials sup-
ported the approval of pregabalin for the treatment
of FM by the US Food and Drug Administration in
June 2007. An international, 14-week trial was also con-
ducted in patients with FM from 16 countries (Australia,
Canada, Denmark, France, Germany, India, Italy, Korea,
Mexico, Portugal, Spain, Sweden, Switzerland, The Neth-
erlands, UK and Venezuela). This international study
demonstrated modest efficacy on pain, PGIC and FIQ
scores with pregabalin 450 mg/day, although data at
300 and 600 mg/day were inconsistent [14], and the
European Medicines Agency (EMA) did not approve
pregabalin for the treatment of FM. Currently, there are
no approved treatments for FM in the European Union.
Results from the current study in Japanese patients were
broadly consistent with those from previous trials, in
which reductions in mean pain score (vs placebo) ranged
from -0.47 to -0.98 [10,12-14], compared with -0.44 in the
current study. In addition, similar proportions of patients
had a ≥30% or ≥50% reduction in their mean pain score,
with 34 to 50% achieving a ≥30% reduction versus 19 to
35% with placebo (compared with 40.4% vs 30.6% in this
study) and 18 to 29% achieving a ≥50% reduction versus
9 to 15% with placebo (compared with 22.8% vs 12.1% in
this study). The NNT to achieve a ≥50% reduction in
mean pain score in these previous studies ranged from
7 to 12 [10,12,14] (compared with 10 in this study).
While the primary objective of this trial was to assess
the effect of pregabalin on the symptomatic relief of pain,
the study also assessed the broader effects of pregabalin
on overall health status and quality of life. Measures such
as PGIC allow patients to provide their own assessment
of their overall health status, taking into consideration
pain and other symptoms together with physical and
emotional functioning, and any adverse effects. This
Table 5 All-cause adverse events
Placebo
N = 248
Pregabalin
N = 250
Adverse events 175 (70.6)a 225 (90.0)
Serious adverse events 1 (0.4) 3 (1.2)
Severe adverse events 0 2 (0.8)
Discontinuations due to adverse events 9 (3.6) 24 (9.6)
Dose reductions/temporary discontinuations due to adverse events 11 (4.4) 30 (12.0)
Frequent adverse eventsb
Somnolence 45 (18.1) 116 (46.4)
Dizziness 15 (6.0) 74 (29.6)
Nasopharyngitis 45 (18.1) 45 (18.0)
Increased weight 9 (3.6) 39 (15.6)
Constipation 17 (6.9) 36 (14.4)
Feeling abnormal 3 (1.2) 20 (8.0)
Peripheral edema 3 (1.2) 18 (7.2)
Headache 15 (6.0) 15 (6.0)
Vision blurred 3 (1.2) 13 (5.2)
aNumber (%) of patients. bReported by ≥5% of patients in any group.
Table 4 MOS-Sleep Scale scores at baseline and final assessment
Assessment Baseline mean
score ± SD
Final assessment LS
mean score ± SE
Placebo-adjusted LS mean change from
baseline with pregabalina
Placebo Pregabalin Placebo Pregabalin Change 95% CI P-value
Sleep disturbanceb 47.7 ± 26.1 48.0 ± 26.5 39.76 ± 1.31 30.27 ± 1.31 -9.48 -13.12, -5.85 <0.0001*
Sleep adequacy 29.0 ± 23.7 28.7 ± 24.5 36.91 ± 1.41 44.39 ± 1.40 7.48 3.58, 11.38 <0.0001*
Quantity of sleep 5.4 ± 1.4 5.6 ± 1.3 5.70 ± 0.06 5.99 ± 0.06 0.29 0.11, 0.47 0.0007*
Awakening short of breath/headache 25.8 ± 26.6 26.2 ± 26.1 22.99 ± 1.36 18.00 ± 1.36 -4.99 -8.77, -1.21 0.0049*
Snoring 26.5 ± 28.7 25.0 ± 28.1 24.19 ± 1.33 29.17 ± 1.33 4.98 1.29, 8.68 0.9958
Somnolence 41.6 ± 23.3 40.5 ± 24.3 36.41 ± 1.29 47.71 ± 1.28 11.31 7.74, 14.87 1.0000
Overall sleep problems index 49.8 ± 17.2 49.7 ± 18.5 42.66 ± 0.96 39.67 ± 0.95 -2.99 -5.65, -0.33 0.0137*
aDifference in mean change from baseline, compared with placebo using the baseline score as covariate. bMOS-Sleep Scale subscales scored from 0 to 100 with
higher scores indicating more of the attribute named in the subscale except for ‘quantity of sleep’, scored from 0 to 24 indicating the number of hours of sleep.
*Indicates statistical significance at the P <0.025 level.
CI, confidence interval; LS, least squares; MOS, Medical Outcomes Study; SD, standard deviation; SE, standard error
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study demonstrated a significant improvement in PGIC
with pregabalin compared with placebo, with 38.6% vs
26.7% of patients reporting that their symptoms were
either “very much improved” or “much improved”. These
results were consistent with prior trials, in which the per-
centage point difference between pregabalin and placebo
in PGIC ranged from 6.2 to 26.0 [10,12-14]. Similarly,
there was a numerical improvement with pregabalin
compared with placebo in all 10 subscales of the FIQ, an
assessment that quantifies the overall impact of FM on
patients’ functioning across the spectrum of problems
associated with the disorder [25]. The improvement was
statistically significant for four of the subscales: feeling
good, pain, fatigue and morning tiredness. There was
also a trend towards improvement with pregabalin com-
pared with placebo in seven of the eight subscales on the
SF-36, statistically significant in two (physical functioning
and vitality).
Sleep disturbance is one of the key clinical domains in
FM [6]. There is a distinct relationship between poor
quality sleep and pain, with pain then potentially leading
to decreased physical functioning and depression [26-28].
In this study, pregabalin significantly improved measures
of sleep by two distinct instruments: the quality of
sleep score and the MOS-Sleep Scale questionnaire. All
measures on the MOS-Sleep Scale questionnaire showed
improvement with pregabalin, with the exception of the
somnolence and snoring subscales. This was not unex-
pected for somnolence, which is a common AE with
pregabalin [16]. The observed improvements in subjec-
tive measures of sleep in this study were consistent with
prior trials of pregabalin in both FM [10-13] and other
conditions, such as restless legs syndrome [29] and var-
ious types of neuropathic pain [30-33]. Pregabalin has
also been shown to significantly improve objective mea-
sures of sleep in a four-week polysomnography study
measuring Wake After Sleep Onset in FM patients [34].
There were no serious or severe treatment-related AEs
observed in this study, although not all patients tolerated
pregabalin and discontinuations and dose reductions
were more common with pregabalin than placebo. The
majority of discontinuations were due to somnolence or
dizziness. The NNH, based on discontinuations from the
study, was higher in this trial (16) than in previous trials
of 450 mg/day pregabalin in FM patients (in which it
ranged from 9 to 11) [10,13,14], potentially influenced
by the somewhat flexible, lower dosing in this study.
A meta-analysis of previous pregabalin trials in neuro-
pathic pain and fibromyalgia concluded that while prega-
balin has proven efficacy, many patients will have little or
no benefit, or will discontinue treatment due to adverse
events, particularly at higher doses, highlighting the
importance of titrating the dose for each patient to
minimize AEs [35]. The higher NNH and similar NNT
numbers in this study, compared with prior trials of preg-
abalin in FM patients, indicate that the risk:benefit profile
was more favorable than in prior trials in the US and
internationally despite there still being a significant dis-
continuation rate with pregabalin in this study (9.6% vs
3.6% with placebo).
Overall, the safety profile of pregabalin in this popula-
tion was consistent with prior clinical trials; the most
common treatment-related AEs with pregabalin being
somnolence and dizziness. Nevertheless, further trials
are needed to assess the long-term safety and tolerability
of pregabalin in Japanese patients with FM. In order to
address this, this trial has been extended into a 52-week,
open-label study (the results of which will be reported
elsewhere).
Conclusions
In this, the first clinical trial in FM patients in Japan,
pregabalin demonstrated significant efficacy in pain
reduction and also improved measures of sleep and
functioning. The drug was generally well tolerated, and
AEs were consistent with prior trials and current pro-
duct labeling. These data suggest that pregabalin may be
an effective treatment option for the relief of pain and
sleep problems in Japanese patients with FM.
Abbreviations
ACR: American College of Rheumatology; AE: adverse event; CI: confidence
interval; C-SSRS: Columbia Suicide Severity Rating Scale; FM: fibromyalgia;
FIQ: Fibromyalgia Impact Questionnaire; HADS: Hospital Anxiety and
Depression Scale; LOCF: last observation carried forward; LS: least squares;
MMRM: mixed-effect model repeated measure; MOS: Medical Outcomes
Study; NNH: number needed to harm; NNT: number needed to treat;
NSAIDs: nonsteroidal anti-inflammatory drugs; PGIC: Patient Global
Impression of Change; SF-36: 36-Item Short Form Health Survey; VAS: visual
analog scale.
Acknowledgements
This study was funded by Pfizer Japan, Inc. Medical writing support was
provided by Joshua Fink PhD, of UBC Scientific Solutions, and funded by
Pfizer, Inc.
We would like to acknowledge the contribution of the study’s principal
investigators: Shinichi Aoki, Hisashi Date, Tomomi Himeno, Hiroshi Inoue,
Akio Iseki, Sadahiko Kameda, Hyeteok Kim, Masamiki Kimura, Tomomasa
Kimura, Keizo Kobayashi, Yoshinobu Koyama, Kojiro Kumagai, Shinichi
Kuwabara, Satoe Matsubayashi, Yoshifuji Matsumoto, Hiroaki Matsuno, Kenji
Miki, Akiko Miyazawa, Akihito Mizutani, Yuko Morita, Yasuhiko Munakata,
Masato Murakami, Shouhei Nagaoka, Shiro Nakayama, Syuji Ohno, Hiroshi
Oka, Kenryo Oka, Yoshinori Okubo, Masanari Omata, Hirofumi Oosaki,
Motohiro Oribe, Yasuhiro Saito, Kenmei Sakata, Yuki Sekiguchi, Kazutoshi
Seto, Eishi Shirasawa, Takao Sugiyama, Kimihiro Suzuki, Masaharu Tajima,
Yoshinari Takasaki, Nobuo Takubo, Toru Tsuda, Fusazo Urano, Ryoichi
Yamazaki and Masao Yukioka.
Author details
1Pfizer Japan, Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan.
2Rheumatic Disease Center, Tokyo Medical University Hachioji Medical
Center, 1163 Tatemachi Hachioji, Tokyo 193-0998, Japan. 3Department of
Psychiatry, Juntendo University School of Medicine, Juntendo University
Nerima Hospital, 3-1-10 Takanodai, Nerima-ku, Tokyo 177-8521, Japan.
4Institute of Innovative Medical Science and Education, Tokyo Medical
University, 6-1-1 Shinjyuku, Shinjyuku-ku, Tokyo 160-8402, Japan.
Ohta et al. Arthritis Research & Therapy 2012, 14:R217
http://arthritis-research.com/content/14/5/R217
Page 9 of 10
Authors’ contributions
KN, HOka, HOhta, MO and MS contributed to the design of the study. HOka
was a principal investigator and KN and CU were sub-investigators on the
study. MO conducted the statistical analysis of the data. All authors had full
access to the study data, contributed to the drafting and critical review of
the manuscript and read and approved the final version.
Competing interests
HOhta, MO and MS are employees of Pfizer Japan, Inc. KN and HOka
received a consultancy fee from Pfizer Japan, Inc. for their participation in
this study. CU declares no competing interests. KN, HOka and CU were not
compensated for their work on this manuscript.
Received: 17 April 2012 Revised: 24 August 2012
Accepted: 17 September 2012 Published: 12 October 2012
References
1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL,
Tugwell P, Campbell SM, Abeles M, Clark P, et al: The American College of
Rheumatology 1990 criteria for the classification of fibromyalgia. Report
of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
2. Clauw DJ, Crofford LJ: Chronic widespread pain and fibromyalgia: what
we know, and what we need to know. Best Pract Res Clin Rheumatol 2003,
17:685-701.
3. Mease P: Fibromyalgia syndrome: review of clinical presentation,
pathogenesis, outcome measures, and treatment. J Rheumatol Suppl
2005, 75:6-21.
4. Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA,
Morea J, Simon L, Strand CV, Williams DA: Fibromyalgia syndrome module
at OMERACT 9: domain construct. J Rheumatol 2009, 36:2318-2329.
5. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS,
Russell IJ, Winfield JB, Yunus MB: The American College of Rheumatology
preliminary diagnostic criteria for fibromyalgia and measurement of
symptom severity. Arthritis Care Res (Hoboken) 2010, 62:600-610.
6. Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L,
Abetz L, Martin SA: Identifying the clinical domains of fibromyalgia:
contributions from clinician and patient Delphi exercises. Arthritis Rheum
2008, 59:952-960.
7. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L: The prevalence and
characteristics of fibromyalgia in the general population. Arthritis Rheum
1995, 38:19-28.
8. Matsumoto M: Epidemiology of fibromyalgia. Pharma Medica 2006,
24:35-39, Japanese.
9. Nishioka K: Research platform for fibromyalgia in Japan. Arthritis Res Ther
2012, 14(Suppl 1):O5.
10. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, Martin SA,
Barrett JA, Haig G: A 14-week, randomized, double-blinded, placebo-
controlled monotherapy trial of pregabalin in patients with fibromyalgia.
J Pain 2008, 9:792-805.
11. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM,
Sharma U: Fibromyalgia relapse evaluation and efficacy for durability of
meaningful relief (FREEDOM): a 6-month, double-blind, placebo-
controlled trial with pregabalin. Pain 2008, 136:419-431.
12. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE,
Young JP Jr, LaMoreaux LK, Martin SA, Sharma U: Pregabalin for the
treatment of fibromyalgia syndrome: results of a randomized, double-
blind, placebo-controlled trial. Arthritis Rheum 2005, 52:1264-1273.
13. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, Sharma U:
A randomized, double-blind, placebo-controlled, phase III trial of
pregabalin in the treatment of patients with fibromyalgia. J Rheumatol
2008, 35:502-514.
14. Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G,
Leon T, Zeiher B: An international, randomized, double-blind, placebo-
controlled, phase III trial of pregabalin monotherapy in treatment of
patients with fibromyalgia. J Rheumatol 2011, 38:2643-2652.
15. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, Bramwell S, Corradini L,
England S, Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T,
Williams D: Identification of the alpha2-delta-1 subunit of voltage-
dependent calcium channels as a molecular target for pain mediating
the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006,
103:17537-17542.
16. Pfizer Inc: LYRICA prescribing information. [http://labeling.pfizer.com/
ShowLabeling.aspx?id=561].
17. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT,
Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N,
Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S,
Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C,
McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, et al:
Interpreting the clinical importance of treatment outcomes in chronic
pain clinical trials: IMMPACT recommendations. J Pain 2008, 9:105-121.
18. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM: Clinical importance
of changes in chronic pain intensity measured on an 11-point numerical
pain rating scale. Pain 2001, 94:149-158.
19. Burckhardt CS, Clark SR, Bennett RM: The fibromyalgia impact
questionnaire: development and validation. J Rheumatol 1991, 18:728-733.
20. Osada K, Oka H, Isomura T, Nakamura I, Tominaga K, Takahashi S, Kojima A,
Nishioka K: Development of the Japanese version of the Fibromyalgia
Impact Questionnaire (JFIQ): psychometric assessments of reliability and
validity. Int J Rheum Dis 2011, 14:74-80.
21. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-
36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
22. Snaith RP, Zigmond AS: The Hospital Anxiety and Depression Scale Manual
London: NFER Nelson; 1994.
23. Cappelleri JC, Bushmakin AG, McDermott AM, Sadosky AB, Petrie CD,
Martin S: Psychometric properties of a single-item scale to assess sleep
quality among individuals with fibromyalgia. Health Qual Life Outcomes
2009, 7:54.
24. Hays RD, Stewart AL: Sleep measures. In Measuring Functioning and Well-
Being. Edited by: Stewart AL, Ware JE Jr. Durham, NC: Duke University Press;
1992:235-239.
25. Bennett R: The Fibromyalgia Impact Questionnaire (FIQ): a review of its
development, current version, operating characteristics and uses. Clin
Exp Rheumatol 2005, 23:S154-162.
26. Harding SM: Sleep in fibromyalgia patients: subjective and objective
findings. Am J Med Sci 1998, 315:367-376.
27. Moldofsky H: The significance of dysfunctions of the sleeping/waking
brain to the pathogenesis and treatment of fibromyalgia syndrome.
Rheum Dis Clin North Am 2009, 35:275-283.
28. Bigatti SM, Hernandez AM, Cronan TA, Rand KL: Sleep disturbances in
fibromyalgia syndrome: relationship to pain and depression. Arthritis
Rheum 2008, 59:961-967.
29. Garcia-Borreguero D, Larrosa O, Williams AM, Albares J, Pascual M,
Palacios JC, Fernandez C: Treatment of restless legs syndrome with
pregabalin: a double-blind, placebo-controlled study. Neurology 2010,
74:1897-1904.
30. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H,
Garofalo EA, Poole RM: Pregabalin for the treatment of postherpetic
neuralgia: a randomized, placebo-controlled trial. Neurology 2003,
60:1274-1283.
31. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK:
Pregabalin in central neuropathic pain associated with spinal cord
injury: a placebo-controlled trial. Neurology 2006, 67:1792-1800.
32. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M: Efficacy of
pregabalin in neuropathic pain evaluated in a 12-week, randomised,
double-blind, multicentre, placebo-controlled trial of flexible- and fixed-
dose regimens. Pain 2005, 115:254-263.
33. van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L:
Efficacy and tolerability of twice-daily pregabalin for treating pain and
related sleep interference in postherpetic neuralgia: a 13-week,
randomized trial. Curr Med Res Opin 2006, 22:375-384.
34. Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM: Effect of pregabalin
on sleep in patients with fibromyalgia and sleep maintenance
disturbance: a randomized, placebo-controlled, 2-way crossover
polysomnography study. Arthritis Care Res (Hoboken) 2012, 64:597-606.
35. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ: Pregabalin for acute
and chronic pain in adults. Cochrane Database Syst Rev 2009, CD007076.
doi:10.1186/ar4056
Cite this article as: Ohta et al.: A randomized, double-blind, multicenter,
placebo-controlled phase III trial to evaluate the efficacy and safety of
pregabalin in Japanese patients with fibromyalgia. Arthritis Research &
Therapy 2012 14:R217.
Ohta et al. Arthritis Research & Therapy 2012, 14:R217
http://arthritis-research.com/content/14/5/R217
Page 10 of 10
